Traders Purchase Large Volume of Corcept Therapeutics Put Options (CORT)

Corcept Therapeutics Incorporated (NASDAQ:CORT) saw unusually large options trading on Friday. Traders purchased 1,200 put options on the stock. This is an increase of approximately 802% compared to the average daily volume of 133 put options.

In other Corcept Therapeutics news, insider Robert S. Fishman sold 8,000 shares of the firm’s stock in a transaction on Friday, December 8th. The stock was sold at an average price of $16.72, for a total transaction of $133,760.00. Following the completion of the sale, the insider now owns 8,000 shares of the company’s stock, valued at $133,760. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director G Leonard Baker, Jr. sold 30,000 shares of the firm’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $17.59, for a total value of $527,700.00. The disclosure for this sale can be found here. 19.20% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Victory Capital Management Inc. purchased a new position in shares of Corcept Therapeutics during the third quarter worth $108,000. BNP Paribas Arbitrage SA boosted its position in shares of Corcept Therapeutics by 2,942.9% during the second quarter. BNP Paribas Arbitrage SA now owns 9,707 shares of the biotechnology company’s stock worth $115,000 after buying an additional 9,388 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of Corcept Therapeutics by 52.6% during the second quarter. PNC Financial Services Group Inc. now owns 9,837 shares of the biotechnology company’s stock worth $116,000 after buying an additional 3,390 shares during the period. Sand Hill Global Advisors LLC purchased a new position in shares of Corcept Therapeutics during the second quarter worth $118,000. Finally, Jasper Ridge Partners L.P. purchased a new position in shares of Corcept Therapeutics during the second quarter worth $118,000. Institutional investors and hedge funds own 64.71% of the company’s stock.

Several equities research analysts have issued reports on CORT shares. Piper Jaffray Companies set a $18.00 target price on Corcept Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 24th. Stifel Nicolaus started coverage on Corcept Therapeutics in a research note on Thursday, August 31st. They set a “buy” rating and a $20.00 target price for the company. Zacks Investment Research cut Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th. Finally, BidaskClub cut Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $18.20.

Corcept Therapeutics (CORT) opened at $16.61 on Monday. Corcept Therapeutics has a 52-week low of $6.70 and a 52-week high of $20.77. The company has a market capitalization of $1,895.60, a price-to-earnings ratio of 57.28 and a beta of 1.89.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.13 by ($0.02). Corcept Therapeutics had a return on equity of 58.17% and a net margin of 27.28%. The firm had revenue of $42.70 million for the quarter, compared to analysts’ expectations of $41.64 million. During the same quarter in the prior year, the business earned $0.02 earnings per share. The company’s quarterly revenue was up 96.8% on a year-over-year basis. analysts forecast that Corcept Therapeutics will post 0.47 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/12/18/traders-purchase-large-volume-of-corcept-therapeutics-put-options-cort.html.

About Corcept Therapeutics

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply